Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Int J Mol Sci
2020 May 27;2111:. doi: 10.3390/ijms21113810.
Show Gene links
Show Anatomy links
Association of A Novel Splice Site Mutation in P/Q-Type Calcium Channels with Childhood Epilepsy and Late-Onset Slowly Progressive Non-Episodic Cerebellar Ataxia.
Stendel C
,
D'Adamo MC
,
Wiessner M
,
Dusl M
,
Cenciarini M
,
Belia S
,
Nematian-Ardestani E
,
Bauer P
,
Senderek J
,
Klopstock T
,
Pessia M
.
???displayArticle.abstract???
Episodic ataxia type 2 (EA2) is characterized by paroxysmal attacks of ataxia with typical onset in childhood or early adolescence. The disease is associated with mutations in the voltage-gated calcium channel alpha 1A subunit (Cav2.1) that is encoded by the CACNA1A gene. However, previously unrecognized atypical symptoms and the genetic overlap existing between EA2, spinocerebellar ataxia type 6, familial hemiplegic migraine type 1, and other neurological diseases blur the genotype/phenotype correlations, making a differential diagnosis difficult to formulate correctly and delaying early therapeutic intervention. Here we report a new clinical phenotype of a CACNA1A-associated disease characterized by absence epilepsy occurring during childhood. However, much later in life the patient displayed non-episodic, slowly progressive gait ataxia. Gene panel sequencing for hereditary ataxias led to the identification of a novel heterozygous CACNA1A mutation (c.1913 + 2T > G), altering the donor splice site of intron 14. This genetic defect was predicted to result in an in-frame deletion removing 44 amino acids from the voltage-gated calcium channel Cav2.1. An RT-PCR analysis of cDNA derived from patient skin fibroblasts confirmed the skipping of the entire exon 14. Furthermore, two-electrode voltage-clamp recordings performed from Xenopus laevis oocytes expressing a wild-type versus mutant channel showed that the genetic defect caused a complete loss of channel function. This represents the first description of distinct clinical manifestations that remarkably expand the genetic and phenotypic spectrum of CACNA1A-related diseases and should be considered for an early diagnosis and effective therapeutic intervention.
Figure 1. The patient presents with cerebellar atrophy and epilepsy. (A) Brain MRI section showing marked atrophy of the cerebellar vermis (T1-weighted image). (B) Brain MRI section showing slight atrophy of the cerebellar hemispheres (T2-weighted image). (C) Interictal EEG showing a frontotemporal spike, most prominent in the temporal leads (FT10, T8, TP10).
Figure 2. The patient carries a c.1913 + 2T > G variant in the CACNA1A gene. Sequencing chromatograms of a partial cDNA sequence of a healthy subject and the affected patient showing (A) exon 13/14 and exon 14/15, and (B) the abnormal junction (AG) between the exon 13 and 15 of the patient. (C) Alignment of the wild-type (top) and mutant (bottom) Cav2.1 protein showing the amino acid sequence that is predicted to be deleted (dashed line) as a consequence of the in-frame mutation.
Figure 3. Localization of the identified splice-site mutation. Membrane topology of a Cav2.1 channel showing the predicted structure which includes four homologous domains (I–IV) with six transmembrane segments (S1–S6) in each domain. The position of the novel c.1913 + 2T > G variant is indicated as a red mark at the beginning of the S4–S5 linker of the II domain. Highlighted in red are shown the regions of the Cav2.1 channel that are predicted to be missed as a result of the mutation. The diagram also shows the localization of single nucleotide substitutions, truncating and splice-site mutations in the secondary structure of the Cav2.1α1 subunit. All CACNA1A missense, nonsense, and splice-site mutations that are depicted in the figure were collected from the HGMD database.
Figure 4. The c.1913 + 2T > G variant deletes exon 14. The RT-PCR analysis of cDNA from patient and control fibroblast using primers flanking exon 14 detected a 259 bp product in the patient. The PCR product obtained from healthy control individuals was 391 bp. A 100 bp DNA ladder was used as a marker to estimate the amplicon size.
Figure 5. The mutation causes the total loss of function of the Cav2.1 channels. (A) Overlaid representative current traces recorded from a Xenopus laevis oocyte injected with wild-type or mutant cDNA for CaV2.1 and auxiliary subunits. Currents were elicited by a depolarizing ramp from –90 mV to +90 mV, lasting 1 s in duration. (B) Bar plot showing the peak whole-cell current amplitudes for the indicated channels. Notice that membrane currents could not be detected (N.D.) in any of the cells injected with mutant cDNA. (C) Bar plot showing the peak whole-cell current amplitudes recorded from oocytes injected with wild-type Cav2.1, co-injected with mutant cDNA (1:1 ratio), or injected with mutant cDNA, together with the accessory subunits. Three different batches of oocytes were collected, and the recorded currents were averaged (data are mean ± SE; for panel B, n = 30 for wild-type; n = 44 for mutant; for panel C, n = 36 for wild-type; n = 26 for wild-type+mutant; n = 59 for mutant; the statistical analysis of graph B revealed a significance of p < 00001, whereas the data reported in graph C were not statistically significant except for the mutant alone).
Figure 6. Structural modelling of Cav2.1 channels. Side view of the homology model of the domains II and IV of the alpha subunit (left). The front and back domains were removed for clarity. The crystal structure of the rabbit Cav1.1 alpha subunit (accession code: 5gjw) was used to show the corresponding structures that are affected by the mutation identified in the patient’s Cav2.1 channel. The relevant helices are highlighted using different colors: S4 (blue), S4–S5 linker (cyan), and S5 (red). On the right-hand side is the top view of the channel to further show the structural and functional relationships between the S4–S5 linker and the voltage-sensor S4, as well as the S5 and the ion conducting pore. The magenta spheres represent the Ca2+ ions located within the selectivity filter. Roman numbers mark the corresponding domains.
Bris,
Bioinformatics Tools and Databases to Assess the Pathogenicity of Mitochondrial DNA Variants in the Field of Next Generation Sequencing.
2018, Pubmed
Bris,
Bioinformatics Tools and Databases to Assess the Pathogenicity of Mitochondrial DNA Variants in the Field of Next Generation Sequencing.
2018,
Pubmed
D'Adamo,
K(+) channelepsy: progress in the neurobiology of potassium channels and epilepsy.
2013,
Pubmed
D'Adamo,
Ion Channels Involvement in Neurodevelopmental Disorders.
2020,
Pubmed
D'Adamo,
New insights into the pathogenesis and therapeutics of episodic ataxia type 1.
2015,
Pubmed
Damaj,
CACNA1A haploinsufficiency causes cognitive impairment, autism and epileptic encephalopathy with mild cerebellar symptoms.
2015,
Pubmed
Eunson,
New calcium channel mutations predict aberrant RNA splicing in episodic ataxia.
2005,
Pubmed
García-Baró-Huarte,
Phenotypic variability in a four generation family with a p.Thr666Met CACNA1A gene mutation.
2014,
Pubmed
Graves,
Premature stop codons in a facilitating EF-hand splice variant of CaV2.1 cause episodic ataxia type 2.
2008,
Pubmed
,
Xenbase
Guida,
Complete loss of P/Q calcium channel activity caused by a CACNA1A missense mutation carried by patients with episodic ataxia type 2.
2001,
Pubmed
Haan,
A review of the genetic relation between migraine and epilepsy.
2008,
Pubmed
Hans,
Functional consequences of mutations in the human alpha1A calcium channel subunit linked to familial hemiplegic migraine.
1999,
Pubmed
Holtmann,
Human epilepsy, episodic ataxia type 2, and migraine.
2002,
Pubmed
Imbrici,
Dysfunction of the brain calcium channel CaV2.1 in absence epilepsy and episodic ataxia.
2004,
Pubmed
,
Xenbase
Imbrici,
Episodic ataxia type 1 mutation F184C alters Zn2+-induced modulation of the human K+ channel Kv1.4-Kv1.1/Kvbeta1.1.
2007,
Pubmed
,
Xenbase
Jodice,
Episodic ataxia type 2 (EA2) and spinocerebellar ataxia type 6 (SCA6) due to CAG repeat expansion in the CACNA1A gene on chromosome 19p.
1997,
Pubmed
Nachbauer,
Episodic ataxia type 2: phenotype characteristics of a novel CACNA1A mutation and review of the literature.
2014,
Pubmed
Ophoff,
Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4.
1996,
Pubmed
Pietrobon,
Calcium channels and migraine.
2013,
Pubmed
Romaniello,
A wide spectrum of clinical, neurophysiological and neuroradiological abnormalities in a family with a novel CACNA1A mutation.
2010,
Pubmed
Salvi,
RNAi silencing of P/Q-type calcium channels in Purkinje neurons of adult mouse leads to episodic ataxia type 2.
2014,
Pubmed
Schöls,
Spinocerebellar ataxia type 6: genotype and phenotype in German kindreds.
1998,
Pubmed
Shapiro,
Identification of subtypes of muscarinic receptors that regulate Ca2+ and K+ channel activity in sympathetic neurons.
2001,
Pubmed
Sinke,
Clinical and molecular correlations in spinocerebellar ataxia type 6: a study of 24 Dutch families.
2001,
Pubmed
Sintas,
Mutation Spectrum in the CACNA1A Gene in 49 Patients with Episodic Ataxia.
2017,
Pubmed
Tonelli,
Early onset, non fluctuating spinocerebellar ataxia and a novel missense mutation in CACNA1A gene.
2006,
Pubmed
Wan,
CACNA1A mutations causing episodic and progressive ataxia alter channel trafficking and kinetics.
2005,
Pubmed
Wu,
Structure of the voltage-gated calcium channel Ca(v)1.1 at 3.6 Å resolution.
2016,
Pubmed
Yabe,
Downbeat positioning nystagmus is a common clinical feature despite variable phenotypes in an FHM1 family.
2008,
Pubmed
Zhuchenko,
Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel.
1997,
Pubmed
